Advertisement

Advertisement

AZN Stock Latest News

AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg

The FlyAstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg

AstraZeneca CFO Reports Vesting-Linked Share Acquisition Under 2021 Performance Plan

PremiumCompany Announcements

AstraZeneca CFO Reports Vesting-Linked Share Acquisition Under 2021 Performance Plan

21h ago

AstraZeneca Chair Michel Demaré Buys Additional Shares in the Company

PremiumCompany Announcements

AstraZeneca Chair Michel Demaré Buys Additional Shares in the Company

21h ago

AstraZeneca upgraded to Hold from Sell at Deutsche Bank

PremiumThe Fly

AstraZeneca upgraded to Hold from Sell at Deutsche Bank

1d ago

AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500

PremiumRatings

AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500

2d ago

Olema Oncology price target lowered to $30 from $48 at Stifel

PremiumThe FlyOlema Oncology price target lowered to $30 from $48 at Stifel

2d ago

Olema selloff on Astra miss ‘significant overreaction,’ says JPMorgan

The Fly

Olema selloff on Astra miss ‘significant overreaction,’ says JPMorgan

2d ago

AstraZeneca reports results from DESTINY-Lung04 trial

The Fly

AstraZeneca reports results from DESTINY-Lung04 trial

2d ago

AstraZeneca reports updated exploratory results from ADAURA trial

PremiumThe Fly

AstraZeneca reports updated exploratory results from ADAURA trial

2d ago

AstraZeneca’s Etcamah misses primary goal in key SERENA-4 breast cancer trial

PremiumCompany Announcements

AstraZeneca’s Etcamah misses primary goal in key SERENA-4 breast cancer trial

2d ago

Olema selloff on AstraZeneca miss a buying opportunity, says Citi

PremiumThe Fly

Olema selloff on AstraZeneca miss a buying opportunity, says Citi

3d ago

AstraZeneca down 2% at $157 after SERENA-4 trial update

PremiumThe Fly

AstraZeneca down 2% at $157 after SERENA-4 trial update

5d ago

AstraZeneca says SERENA-4 trial did not meet primary objective

PremiumThe FlyAstraZeneca says SERENA-4 trial did not meet primary objective

5d ago

AstraZeneca’s ATTR-CM Imaging Sub-study Wraps Up, Setting the Stage for New Data Insights

Company Announcements

AstraZeneca’s ATTR-CM Imaging Sub-study Wraps Up, Setting the Stage for New Data Insights

5d ago

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

The Fly

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

6d ago

Rajan Sharma Initiates Buy on AstraZeneca, Citing Robust Pipeline, Strong Financials, and Undervalued Growth Potential

PremiumRatings

Rajan Sharma Initiates Buy on AstraZeneca, Citing Robust Pipeline, Strong Financials, and Undervalued Growth Potential

7d ago

AstraZeneca initiated with an Outperform at RBC Capital

PremiumThe Fly

AstraZeneca initiated with an Outperform at RBC Capital

8d ago

AstraZeneca’s Imfinzi–Imdelltra Combo Delivers Landmark Survival Gains in Small Cell Lung Cancer

PremiumCompany Announcements

AstraZeneca’s Imfinzi–Imdelltra Combo Delivers Landmark Survival Gains in Small Cell Lung Cancer

8d ago

Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint

PremiumThe Fly

Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint

8d ago

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

PremiumThe FlyAstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

8d ago

Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss

Market News

Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss

8d ago

AstraZeneca says tozorakimab demonstrates reduction in COPD exacerbations

The Fly

AstraZeneca says tozorakimab demonstrates reduction in COPD exacerbations

8d ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >